| 标题 |
[求助补充材料]
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial 相关领域
医学
紫杉烷
前列腺癌
肿瘤科
雄激素受体
内科学
雄激素剥夺疗法
临床试验
癌症
乳腺癌
|
| 网址 | |
| DOI | |
| 其它 |
Clinical Trial Lancet . 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial Michael J Morris 1, Daniel Castellano 2, Ken Herrmann 3, Johann S de Bono 4, Neal D Shore 5, Kim N Chi 6, Michael Crosby 7, Josep M Piulats 8, Aude Fléchon 9, Xiao X Wei 10, Hakim Mahammedi 11, Guilhem Roubaud 12, Hana Študentová 13, James Nagarajah 14, Begoña Mellado 15, Álvaro Montesa-Pino 16, Euloge Kpamegan 17, Samson Ghebremariam 17, Teri N Kreisl 17, Celine Wilke 18, Katja Lehnhoff 18, Oliver Sartor 19, Karim Fizazi 20; PSMAfore Investigators Affiliations Expand PMID: 39293462 PMCID: PMC12121614 DOI: 10.1016/S0140-6736(24)01653-2 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
|
温馨提示:该文献已被科研通 学术中心 收录,前往查看
科研通『学术中心』是文献索引库,收集文献的基本信息(如标题、摘要、期刊、作者、被引量等),不提供下载功能。如需下载文献全文,请通过文献求助获取。
|